Full Press Release Details
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), will be presented at the Endocrine Society (ENDO) annual meeting in Boston (June 3) and the Heart in Diabetes (HiD) conference in Philadelphia (June 7).
ENDO 2024, Boston Convention & Exhibition Center
Late-Breaking Poster Presentation: Open-label Results From GRACE, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of Endogenous Hypercortisolism (Cushing Syndrome)
Date & Time: Monday, June 3, 2024, 12:00-1:30 pm ET
Presenter: Rosario Pivonello, MD, PhD, Principal Investigator of the GRACE study and Professor of Endocrinology at Università Federico II di Napoli, Italy
Session: P108 - Late-Breaking Poster Presentations: Day 3
8th Heart in Diabetes Conference, Hilton Penn’s Landing
Oral Presentation: Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
Date & Time: Friday, June 7, 2024, 3:50-4:00 pm ET
Presenter: Ralph DeFronzo, MD, chief of the Diabetes Division and professor of medicine at UT Health San Antonio
Session: Hypercortisolism Implication to Cardiorenal & Metabolic Diseases
Oral Presentation: Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Date & Time: Friday, June 7, 2024, 4:00-4:20 pm ET
Presenter: Rosario Pivonello, MD, PhD, Principal Investigator of the GRACE study and Professor of Endocrinology at Università Federico II di Napoli, Italy
Session: Hypercortisolism Implication to Cardiorenal & Metabolic Diseases
Each of the above presentations will be available on Corcept.com following the event.
Relacorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders in addition to Cushing’s syndrome, including ovarian, adrenal and prostate cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. Relacorilant has orphan drug designation in the United States and the European Union for the treatment of Cushing’s syndrome.
About Corcept Therapeutics
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit Corcept.com.
Forward-Looking Statements
Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, our ability to operate our business; risks related to the study and development of Korlym, relacorilant, dazucorilant, miricorilant and our other product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. These and other risks are set forth in our SEC filings, which are available at our website and the SEC’s website.
In this press release, forward-looking statements include those concerning: relacorilant, including its clinical attributes and potential to become a treatment for patients with Cushing’s syndrome or any other disorder, regulatory oversight of relacorilant, its commercial prospects and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release.